Ipsen to acquire U.S.-based Epizyme for $247 million.
June 27, 2022 at 02:12 AM EDT
The primary focus of the acquisition is the lead medicine, Tazverik, which was granted FDA accelerated approval in 2020
Photography by Christophe Tomatis